biOasis Advances Its Lysosomal Storage Disease Program with a Knockout Model for Sandhoff Disease

VANCOUVER, BRITISH COLUMBIA--(Marketwired - Sept. 9, 2014) - BIOASIS TECHNOLOGIES INC. (OTCQX:BIOAF)(TSX VENTURE:BTI), announces the commencement of a new phase of its Lysosomal Storage Disease program with a study focused on a knockout model for Sandhoff Disease. The study, to be conducted at The University of British Columbia ("UBC"), will assess the use of therapeutics based on biOasis' proprietary Blood-Brain Barrier vectors, Transcend and Transcend^(pep), to correct enzyme deficiencies within the Central Nervous Systems of genetically engineered animals deficient in the enzyme β-hexosaminidase subunit beta ("HEXB"), which is functionally deficient in sufferers of Sandhoff Disease.

The colony of HEXB-deficient animals that populate the "knockout" model have been under development for several months in the UBC laboratory of biOasis' founding scientist, Dr. Wilfred Jefferies of the University's renowned Michael Smith Laboratories. The animals will undergo six weeks of treatment with biOasis' proprietary therapeutics, fMTf-HEXB, a fusion protein consisting of Transcend and β-hexosaminidase subunit beta, and fMTfp-HEXB, a fusion protein consisting of Transcend^(pep) and β-hexosaminidase subunit beta. The treatment period will commence in October when the colony's age and weight are ideal for treatment.

This is the first study where biOasis is utilizing fusion protein versions of its platform technologies. Both fMTf-HEXB and fMTfp-HEXB are classified as chimeric fusion proteins, hybrid proteins that are made of polypeptides that have varying functions or physico-chemical patterns. In the past, biOasis has used chemical conjugation methods to produce therapeutics for test purposes. The method was used because it is faster and less expensive for "proof of concept" purposes. However, chemical conjugations generally do not produce consistent molecular structures. biOasis' chimeric fusion proteins are designed to guarantee that each therapeutic is produced in a structurally consistent manner and that the binding sites of the respective Transcend and Transcend^(pep) molecules are not masked, theoretically enhancing both the binding activity and the transport of therapeutics across the Blood-Brain Barrier.

"Our recent discovery and subsequent validation of Transcend^(pep) as a carrier or shuttle of therapeutics into the brain are extremely encouraging. We now plan to treat animal that lack the HEXB enzyme and therefore mimic the human form of Sandhoff disease with the HEXB-Transcend^(pep) fusion molecules. This is a crucial step towards advancing this novel therapeutic approach to the clinic," said lead researcher, Professor Jefferies.

"This study at UBC kicks off a new phase of our LSD program," said Rob Hutchison, CEO of biOasis Technologies. "All of the work that we and our partners have been doing with Transcend^(pep) has given us the confidence that this program has the potential to be of great value for biOasis and its shareholders. To optimize the program, our team along with help from one of our partners, have worked to prepare clinically acceptable test materials and to this end, we're introducing fusion-based therapeutics rather than those that are chemically conjugated. After a lot of hard work and extensive planning, we're very pleased to be advancing our LSD program with this pivotal study."

About Sandhoff Disease

http://ghr.nlm.nih.gov/condition/sandhoff-disease

About biOasis

biOasis Technologies Inc. is a biopharmaceutical company headquartered in Vancouver, Canada focused on overcoming the limitations of therapeutic drug delivery across the BBB. The company is developing and commercializing a proprietary brain delivery technology to address unmet medical needs in the treatment of central nervous system disorders. biOasis trades on the OTCQX under the symbol "BIOAF" and on the TSX Venture Exchange under the symbol "BTI". For more information about the company please visit www.bioasis.ca.

Forward-Looking Statements

Certain statements in this press release contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 or forward-looking information under applicable Canadian securities legislation that may not be based on historical fact, including without limitation statements containing the words "believe", "may", "plan", "will", "estimate", "continue", "anticipate", "intend", "expect" and similar expressions. Such forward-looking statements or information involve known and unknown risks, uncertainties and other factors that may cause our actual results, events or developments, or industry results, to be materially different from any future results, events or developments express or implied by such forward-looking statements or information. Such factors include, among others, our stage of development, lack of any product revenues, additional capital requirements, risk associated with the completion of clinical trials and obtaining regulatory approval to market our products, the ability to protect our intellectual property, dependence on collaborative partners and the prospects for negotiating additional corporate collaborations or licensing arrangements and their timing. Specifically, certain risks and uncertainties that could cause such actual events or results expressed or implied by such forward-looking statements and information to differ materially from any future events or results expressed or implied by such statements and information include, but are not limited to, the risks and uncertainties that: products that we develop may not succeed in preclinical or clinical trials, or future products in our targeted corporate objectives; our future operating results are uncertain and likely to fluctuate; we may not be able to raise additional capital; we may not be successful in establishing additional corporate collaborations or licensing arrangements; we may not be able to establish marketing and the costs of launching our products may be greater than anticipated; we have no experience in commercial manufacturing; we may face unknown risks related to intellectual property matters; we face increased competition from pharmaceutical and biotechnology companies; and other factors as described in detail in our filings with the Canadian securities regulatory authorities at www.sedar.com. Given these risks and uncertainties, you are cautioned not to place undue reliance on such forward-looking statements and information, which are qualified in their entirety by this cautionary statement. All forward-looking statements and information made herein are based on our current expectations and we undertake no obligation to revise or update such forward- looking statements and information to reflect subsequent events or circumstances, except as required by law.

On Behalf of the Board of Directors

Rob Hutchison, Chairman & CEO

"Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release"